Table 4

Multivariable* OR of biologic or targeted synthetic disease-modifying antirheumatic drugs at each binary level of the COVID-19 severity scale (N=2869)

COVID-19 outcomeAbataceptRituximabIL-6 inhibitorsJAK inhibitorsTNF inhibitors
OR
(95% CI)
P valueOR
(95% CI)
P valueOR
(95% CI)
P valueOR
(95% CI)
P value
Hospitalised1.18 (0.76 to 1.82)0.474.53 (3.32 to 6.18)<0.010.84 (0.53 to 1.33)0.452.40 (1.78 to 3.24)<0.01Ref
Hospitalised with oxygenation/ventilation or death1.12 (0.70 to 1.81)0.632.87 (2.03 to 4.06)<0.010.72 (0.43 to 1.20)0.201.55 (1.04 to 2.18)0.01Ref
Death1.46 (0.72 to 2.89)0.304.57 (3.32 to 9.01)<0.011.13 (0.50 to 2.59)0.772.04 (1.58 to 2.65)<0.01Ref
Mechanical ventilation (restricted to only hospitalised patients, n=613)1.41 (0.94 to 2.10)0.094.05 (3.08 to 5.33)<0.010.75 (0.51 to 1.10)0.142.03 (1.56 to 2.62)<0.01Ref
Mechanical ventilation or death1.14 (0.78 to 1.66)0.504.44 (3.39 to 5.82)<0.010.74 (0.50 to 1.09)0.122.02 (1.56 to 2.61)<0.01Ref
  • *Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer and rheumatoid arthritis disease activity.

  • csDMARD, conventional synthetic disease-modifying antirheumatic drug; IL-6, interleukin 6; JAK, Janus kinase; Ref, reference; TNF, tumour necrosis factor.